본문으로 건너뛰기
← 뒤로

Cell-free chromatin state tracing reveals disease origin and therapy responses.

1/5 보강
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
549 patients with inflammatory bowel disease, colorectal cancer, coronary heart disease or lymphoma.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Of note, our study leverages holistic epigenetic signatures, independently of knowledge of gene transcription, to accurately report recurrence risk and therapeutic response. Together, these findings establish cf-EpiTracing as an automated, non-invasive, epigenome-centric framework with broad applications in early diagnosis, molecular subtyping and prognostic prediction.

Chen X, Meng X, Zhang W, Zhang X, Zhang Y, Yang P, Liu Y, Bao F, Li S, Wang J, Yan C, Li C, Zhang L, Hao X, Liu J, Sun J, Wang Z, Tian Y, Zhu L, Hou Y, Liu Z, Li W, Mi L, Qi X, Yue Y, Du P, Chen G, Zheng J, Dou L, Jing H, He A

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Cell-free DNA in blood originates from fragmented chromatin released by dying cells from both healthy and diseased tissues.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Chen X, Meng X, et al. (2026). Cell-free chromatin state tracing reveals disease origin and therapy responses.. Nature. https://doi.org/10.1038/s41586-026-10224-0
MLA Chen X, et al.. "Cell-free chromatin state tracing reveals disease origin and therapy responses.." Nature, 2026.
PMID 41781618 ↗

Abstract

Cell-free DNA in blood originates from fragmented chromatin released by dying cells from both healthy and diseased tissues. These fragments carry rich molecular modalities that can reveal pathological alterations in tissues of origin. Here we develop cf-EpiTracing, a highly sensitive automated platform that profiles histone modifications in cell-free DNA from as little as 50 μl of human plasma. By integrating multimodal chromatin states with machine learning, cf-EpiTracing enables accurate deconvolution of cell types of origin. We generated 2,417 cf-EpiTracing profiles from plasma of 125 healthy individuals and 549 patients with inflammatory bowel disease, colorectal cancer, coronary heart disease or lymphoma. cf-EpiTracing enabled unbiased identification of primary diseased tissues and other organ involvement, stratification of B cell lymphoma subtypes with different genetic and epigenetic underpinnings, and detection of early-stage diseases or lesions. Surveying dynamics of epigenetic signatures uncovered disease transformation from follicular lymphoma to diffuse large B cell lymphoma. Further, cf-EpiTracing revealed genomic translocations and epigenetic alterations in patients with mantle cell lymphoma. Of note, our study leverages holistic epigenetic signatures, independently of knowledge of gene transcription, to accurately report recurrence risk and therapeutic response. Together, these findings establish cf-EpiTracing as an automated, non-invasive, epigenome-centric framework with broad applications in early diagnosis, molecular subtyping and prognostic prediction.

같은 제1저자의 인용 많은 논문 (5)